2017 Kern Lipid Conference

2017年科恩脂质会议

• 批准号: 9396189
• 负责人: Robert H Eckel
• 金额: $ 1万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9396189
• 关键词: Academia; Address; Affect; Animal Model; Anti-Bacterial Agents; Area; Atherosclerosis; Award; Behavior Disorders; Bile Acids; Biological Markers; Biological Models; Biological Sciences; Biotechnology; Boston; Brain; Cardiovascular Diseases; Cardiovascular system; Child; Cholestasis; Chronic; Chronic Disease; Clinic; Colorado; Complex; Data; Development; Diabetes Mellitus; Disease; Disease model; Dyslipidemias; Ensure; Environment; Explosion; Faculty; Feedback; Fibroblast Growth Factor; Functional disorder; GPBAR1 gene; Gastric Bypass; Genetic; Genome; Goals; Health; Hepatocyte; Hormonal; Human; Human Microbiome; Immune system; Industry; Inflammation; Inflammatory; Informatics; Institutes; International; Kidney; Kidney Diseases; Lipids; Lipoproteins; Liver; Liver diseases; Medical; Medicine; Metabolic; Metabolic Diseases; Metabolism; Metformin; Michigan; MicroRNAs; Microbe; Natural Immunity; Obesity; Organ; Participant; Pathologic; Pathway interactions; Pennsylvania; Pharmacologic Substance; Postdoctoral Fellow; Process; Raja; Reaction; Recycling; Renaissance; Research; Research Personnel; Resolution; Resort; Risk Factors; Role; Science; Scientist; Sequence Analysis; Steatohepatitis; Structure; Synapses; System; Therapeutic; Time; Tissues; Translating; Translations; United States National Institutes of Health; Universities; Update; Weight; Work; authority; base; career; cooking; experience; graduate student; gut microbiome; human disease; insight; lectures; lipid metabolism; meetings; member; metabolome; metabolomics; microbial; microbiome; mouse model; non-alcoholic fatty liver; nonalcoholic steatohepatitis; novel; novel therapeutic intervention; novel therapeutics; nutrition; pathway tools; posters; prevent; professor; receptor; reconstitution; skills; small molecule; social; symposium; targeted treatment; translational approach

Abstract The Kern Lipid Conference, first held in 1985 and held annually since then, focuses on the interactions between lipid metabolism and chronic human disease states, spanning atherosclerotic cardiovascular disease, obesity, diabetes, and liver disease. Since its inception, the overall goals of the have continued to be: 1) promoting science relating to broad areas of lipid metabolism; 2) increasing understanding of the pathobiology of dyslipidemia; 3) providing an open forum for scientists from both academia and industry to meet and discuss the latest research findings related to lipid metabolism; 4) ensuring at least 25% of meeting participants are early career scientists (graduate students, postdoctoral fellows, and Assistant Professors); and 5) providing a unique meeting format in which 50% of the time is devoted to formal presentations and 50% is for open discussions of the presentations. The 2017 Kern Lipid Conference, entitled “The Gut Microbiome, Bile Acids, and Regulatory Networks in Health and Disease: Emerging Therapeutic Approaches” continues this impressive tradition and will be held August 7-9, 2017 at the Vail Marriott Mountain Resort in Vail, CO. The Conference will be co- chaired by Jacob Friedman, Margrit Schwartz, and Michael Trauner. The meeting will provide a forum for discussing novel pathways within the microbiome space that cross-talk with cardio-renal and liver diseases including bile acids and their sequelae, and how new pathways and tools are being used to understanding these pathways and translated into new therapies for important and intractable disorders such as steatohepatitis. Salient features of the meeting include four scientific sessions with prominent speakers, three poster sessions, and a roundtable discussion involving accomplished scientists from academia and industry. The four speaking sessions will address; 1) Connections and Cross-talk with the microbiome; 2) Liver Diseases-GI, NASH, Cholestasis; 3) Cardiovascular and Kidney disease; and 4) CNS and Gut Cross-Talk. Well-defined mechanisms for encouraging the participation of young scientists (including presenting prestigious awards to early career participants), a structure that facilitates interaction and discussion through both formal and informal means, and the confirmed participation of internationally recognized authorities makes it likely that novel insights leading to potential new translational approaches for microbial-related disease will emerge from the 2017 Conference.

摘要 克恩脂质会议于1985年首次举行，此后每年举行一次，重点关注 脂质代谢和慢性人类疾病状态，包括动脉粥样硬化性心血管疾病，肥胖症， 糖尿病和肝病。自成立以来，其总体目标一直是：1）促进 与脂质代谢的广泛领域有关的科学; 2）增加对 血脂异常; 3）为来自学术界和工业界的科学家提供一个开放的论坛， 与脂质代谢有关的最新研究成果; 4）确保至少25%的与会者提前参加会议 职业科学家（研究生，博士后研究员和助理教授）; 5）提供独特的 会议形式，其中50%的时间用于正式演讲，50%用于公开讨论 介绍。2017年克恩脂质会议，题为“肠道微生物组，胆汁酸和监管” 健康与疾病网络：新兴治疗方法”延续了这一令人印象深刻的传统 并将于2017年8月7日至9日在美国科罗拉多州韦尔的韦尔万豪度假村举行。 由雅各布·弗里德曼、玛格丽特·施瓦茨和迈克尔·特劳纳主持。会议将提供一个论坛， 讨论微生物组空间内与心肾和肝脏疾病相互作用的新途径 包括胆汁酸及其后遗症，以及如何使用新的途径和工具来了解这些 并转化为治疗脂肪性肝炎等重要和难治性疾病的新疗法。 会议的突出特点包括由著名发言人参加的四次科学会议，三次海报会议， 以及来自学术界和工业界的有成就的科学家参加的圆桌讨论。四个说话的人 会议将解决; 1）与微生物组的连接和串扰; 2）肝脏疾病-GI，NASH， 胆汁淤积; 3）心血管和肾脏疾病;以及4）CNS和肠道串扰。明确的机制 鼓励年轻科学家的参与（包括为早期职业生涯颁发著名奖项） 一个通过正式和非正式手段促进互动和讨论的结构，以及 国际公认的权威机构的确认参与，使人们有可能提出新的见解， 微生物相关疾病的潜在新转化方法将在2017年会议上出现。